A5103108816- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Ethics in Clinical Research
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Protein purification and stability
- Ubiquitin and proteasome pathways
- Statistical Methods in Clinical Trials
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Protein Degradation and Inhibitors
- Cutaneous Melanoma Detection and Management
- PI3K/AKT/mTOR signaling in cancer
- Medical Imaging and Pathology Studies
- Digestive system and related health
- Pharmacogenetics and Drug Metabolism
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- Genetic factors in colorectal cancer
- Hormonal and reproductive studies
- Nanoplatforms for cancer theranostics
- Photodynamic Therapy Research Studies
- Sexual Differentiation and Disorders
- Advanced Neural Network Applications
Dana-Farber Cancer Institute
2023-2024
The University of Texas MD Anderson Cancer Center
2005-2023
Roswell Park Comprehensive Cancer Center
2023
Harvard University
2023
University at Buffalo, State University of New York
2023
Colby College
2023
Frederick National Laboratory for Cancer Research
2020
Duke University
2020
Amgen (United States)
2009
Checkpoint immunotherapy has yielded meaningful responses across many cancers but shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7-H3/CD276) is an immune checkpoint molecule and emerged as a promising therapeutic target. However, much remains to be understood regarding B7-H3's role cancer progression, predictive biomarkers for B7-H3-targeted therapy, combinatorial strategies. Our multi-omics analyses identified B7-H3 one of the most abundant checkpoints tumors...
Deep learning is rapidly becoming the technique of choice for automated segmentation nuclei in biological image analysis workflows. In order to evaluate feasibility training nuclear models on small, custom annotated datasets that have been augmented, we designed a computational pipeline systematically compare different model architectures and strategies. Using this approach, demonstrate transfer tuning parameters, such as composition, size, preprocessing dataset, can lead robust models,...
Testosterone deficiency (TD, total testosterone ≤350 ng/dL [12.15 nmol L-1 ]) and obesity epidemic are growing in parallel the United States. Yet, sequelae of TD on risk mortality remain unclear.To investigate whether co-occurrence overall (body mass index ≥30 kg/m2 ), abdominal (waist circumference ≥102 cm), is associated with a all-cause American men.The data were obtained from NHANES 1999-2004 Linked Mortality File (December 31, 2011). A 948 participants aged ≥20 years old endogenous sex...
8553 Background: NUT carcinoma (NC) is an underdiagnosed, poorly differentiated squamous cell cancer with a median survival of 6.7 months. NC defined and driven by NUTM1 fusions; fusion oncoproteins enhance oncogene transcription, including that MYC. The ability standard NGS assays to identify fusions unknown other molecular features are undefined. Methods: Patients (pts) who consented participate in worldwide registry whose tumors underwent care (SOC) broad panel (>80 genes) DNA, ctDNA,...
The cyclin D1-Cyclin-Dependent Kinases 4 and 6 (CDK4/6) complex is crucial for the development of melanoma. We previously demonstrated that targeting CDK4/6 using small molecule inhibitors (CDK4/6i) suppresses BrafV600E melanoma growth in vitro vivo through induction cellular senescence. Clinical trials investigating CDK4/6i have not yielded successful outcomes, underscoring necessity to enhance therapeutic efficacy CDK4/6i. Accumulated research has shown while senescence initially cell...
We present the first known case of a patient with
4671 Background: Although strontium-89 has been used for the treatment of bone metastases, its long-term effects remain unclear. We assessed rate marrow failure in patients with prostate cancer who had received a dose strontium-89. Methods: This subgroup analysis involved 34 androgen-independent and metastases given six weekly doses doxorubicin consolidation after response to induction chemotherapy. subsequent hematotoxicity terms ability tolerate additional treatments during median 25...
Lung cancer is commonly caused by activating mutations in the epidermal growth factor receptor (EGFR). Allosteric kinase inhibitors are unaffected common ATP-site resistance and represent a promising therapeutic strategy for targeting drug-resistant EGFR variants. However, allosteric antagonized dimerization, understanding this phenomenon has been limited to cellular experiments. To facilitate study of inhibitor pharmacology, we designed purified constitutive dimer harboring clinically...
1523 Background: To identify genes that distinguish between treatments, tumor types, and their interaction, we undertook a microarray analysis of tissue in preoperative chemoprevention study L-selenomethionine (SeMet) vitamin E (VE) prostate cancer. Methods: Forty-eight men with cancer were enrolled single-institution, double-blind, placebo-controlled trial randomized patients into four groups receiving 200 μg SeMet, 400 IU VE, combination the two, or placebo (see 2006 ASCO abstract 1007)....
8105 Background: The majority of NSCLC patients (pts) with activating epidermal growth factor receptor (EGFR) mutations respond to gefitinib, however acquired resistance this tyrosine kinase inhibitor (TKI) ensues. secondary resistant T790M mutation has been identified in 50% progressing pts. amplification the MET oncogene occurs 20% TKI-resistant pts and sometimes concomitantly T790M. Very few other (D761Y, L747S) exist. Our goal was determine effects erlotinib 150mg/d EGFR mutated who...
4684 Background: Androgen ablation has been the cornerstone of treatment for patients (pts) with androgen-dependent prostate cancer (ADPC) who relapsed after initial local therapies. IM862, a naturally occurring dipeptide (L-glu-L-trp) immunomodulatory and anti-angiogenic properties, produced significant anti-cancer activity in Kaposi’s sarcoma. The goal this study was to explore novel agent that can inhibit progression synergistically androgen ablation. Methods: Eighty-four pts ADPC had PSA...
1007 Background: To identify and assess biomarkers modulated by prostate cancer chemopreventive agents, we created a model that, exploiting the time between histologic diagnosis of definitive therapy (prostatectomy), expedites tissue cross comparison confronts multifocality multizonal heterogeneity cancer. Methods: Between February 2001 April 2002, 48 presurgical patients were enrolled in single-institution, randomized, double-blind trial vitamin E (VE) L-selenomethionine (SeMET) based on...